Prokarium Ltd is a clinical stage SME with a dual business model: Development of in-house oral vaccines and out-licensing of its Vaxonella oral vaccine delivery platform. Currently the focus is on developing vaccines to prevent Chlamydia ($6bn market), Clostridium difficile ($860mn), and exacerbations of COPD and asthma ($3.6bn). Prokarium current investor is Flerie Invest AB, a Swedish investor focused on life science investments globally. Flerie is continuing to invest as part of an ongoing Series B raise of £18M/$25M.

If you are interested to know more about investing in Prokarium, please contact us to obtain the latest slide deck explaining the investment opportunity.

Partnering with organisations interested in using the Vaxonella® platform is also a priority for Prokarium. If you have a vaccine candidate that you want to evaluate in an oral vaccine delivery platform, with the advantages of a single manufacturing platform, strong mucosal immune response and ease of manufacture, then we can offer to clone your antigens into our platform for you to evaluate in your established preclinical models. For more details on the advantages of oral delivery using Vaxonella, see the Technology section.